Microcap Ledger Fractyl Health, Inc. $GUTS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Burlington, MA
- Fiscal year end
- December 31
- Shares outstanding
- 159,179,848 [10-Q 2026-08-10]
What the company doesAI summary of filing
Fractyl Health develops medical devices and gene therapy candidates for metabolic and weight management indications. The company's lead product, Revita, is a medical device that performs hydrothermal ablation of the duodenal mucosa for weight loss maintenance and has received FDA Breakthrough Device designation; Revita has CE mark approval in Europe under the Medical Device Directive and the company is working toward MDR certification. Fractyl is also developing Rejuva gene therapy candidates using AAV vectors, which are expected to be regulated as biologic-device combination products and are currently in preclinical and early clinical stages. The company is pre-revenue and dependent on obtaining regulatory approvals and clinical study success to commercialize its products, with reimbursement and healthcare coverage decisions being critical to market adoption. [10-K 2026-03-24]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$16.32M | −$38.38M | $47.14M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | $0.00 | −$140.95M | −$90.33M | $81.54M | [10-K 2026-03-24] |
| FY ended Dec 2024 | $93.0K | −$68.69M | −$65.52M | $67.46M | [10-K 2026-03-24] |
- Quarterly cash burn
- −$19.19M
- Cash runway Estimate
- ~7.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 48,098,944 | [10-Q 2024-11-12] |
| 2025-02-21 | 48,920,221 | [10-K 2025-03-03] |
| 2025-05-02 | 48,976,636 | [10-Q 2025-05-13] |
| 2025-08-01 | 50,289,014 | [10-Q 2025-08-12] |
| 2025-10-31 | 137,044,440 | [10-Q 2025-11-12] |
| 2026-03-01 | 158,648,963 | [10-K 2026-03-24] |
| 2026-05-01 | 158,648,963 | [10-Q 2026-05-12] |
| 2026-08-04 | 159,179,848 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2025-03-03; declared effective 2025-03-18 [S-3 2025-03-03]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-11. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-11 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-11] |
| 2026-03-17 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-17] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-14 | Bradley William | buy | 64,516 | $0.62 | [4 2026-09-16] |
| 2026-06-12 | Royan Ajay | buy | 23,000 | $0.85 | [4 2026-06-15] |
| 2026-06-10 | Bradley William | buy | 68,493 | $0.73 | [4 2026-06-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-01 | 8-K | Charter, bylaws or fiscal year change |
| 2026-09-24 | 8-K | Shareholder vote results |
| 2026-09-11 | 8-K | Listing notice or transfer |
| 2026-08-24 | DEF 14A | Proxy statement |
| 2026-08-14 | PRE 14A | Proxy statement |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations |
| 2026-07-15 | 8-K | Regulation FD disclosure; Other events |
| 2026-06-11 | 8-K | Shareholder vote results |
| 2026-06-04 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $GUTS
Email me when Fractyl Health, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.